Posted by Michael Wonder on 29 Jun 2023
Genprex receives US FDA fast track designation for Reqorsa immunogene therapy in combination with Tecentriq for the treatment of small cell lung cancer
28 June 2023 - Third FDA fast track designation further validates the potential of Reqorsa.
Genprex today announced that the US FDA has granted fast track designation for the Company's lead drug candidate, Reqorsa immunogene therapy, in combination with Genentech's Tecentriq in patients with extensive-stage small cell lung cancer who did not develop tumour progression after receiving Tecentriq and chemotherapy as initial standard treatment.
